Press Releases

Huateng Pharma to Attend CPHI Barcelona 2023

Huateng Pharma will be attending CPhI Worldwide, Booth 3C02, Hall 3.

SMi Systems secures UK patent for breakthrough single molecule imaging capabilities

SMi Systems has secured a patent from the UK Intellectual Property Office for the single-molecule imaging technologies that underpin its super-resolution multi-omic platform.

Invitation to learn from the best: Evening of insights and networking will honor a clinical data management stalwart

Invitation to learn from the best: Evening of insights and networking will honor a clinical data management stalwart Prof Deborah Ashby to give the 2023 Sally Hollis Memorial Lecture in Macclesfield

Belong.Life Launches New Conversational AI SaaS Solution for Cancer Clinical Trial Matching and Recruitment

Tara is a SaaS-based conversational AI cancer clinical trial matching platform for health providers and contract research organizations (CROs). The solution is designed to accelerate the process of matching patients with eligible clinical trials, enabling increased recruitment at significantly lower costs. Tara is the second product in Belong’s AI Health Mentor suite of solutions.

Torx® Software announces global drug discovery collaboration with CDD Vault®

Torx® Software Limited has launched a major international collaboration with CDD Vault, which will create a shared digital ecosystem for drug discovery data

Launch of high-quality (pre-clinical) enzymes suitable for pre-clinical and process development in mRNA vaccine and therapeutics

Takara Bio Europe has announced the launch of new high-quality grade mRNA production enzymes suitable for pre-clinical and process development in mRNA vaccine and therapeutic manufacturing.

Tower continues innovation streak with new product launch at CPHI Barcelona

Temperature-controlled container specialist, Tower Cold Chain will be exhibiting its latest concept and products at the world’s largest pharmaceutical event, CPHI.

BioIVT Completes XenoTech Integration, Highlights Expanded ADME-Tox Research Services at the North American ISSX Meeting

BioIVT has implemented new tiered ‘fit-for-purpose’ study designs for metabolism, drug-drug interaction, and transporter programs.

New Educational Initiative, Clinical Trials For All, to Drive More Understanding, Participation, and Diversity

Amerigo Scientific Releases FSB Solution Products to Expedite Alzheimer’s Disease Research

Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics’ CTx-1301 Phase III Laboratory Classroom Study in ADHD Patients

Dr. Vince Clinical Research (DVCR), a full-service clinical research organization (CRO), today announced the first dosing in Cingulate Therapeutics’ CTx-1301 Phase III dose-optimization onset and duration laboratory classroom study.

iotaSciences and Quantum Design China Enter into Distribution Agreement

iotaSciences and Quantum Design China announced today an exclusive distribution agreement for iotaSciences proprietary single cell handling platforms in China.

Recipharm partners with Ahead Therapeutics to develop rare autoimmune disease therapy

About Recipharm Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical and biopharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical and biologics product development, and development and manufacturing of medical devices. Recipharm manufactures several hundred different products for customers ranging from big pharma to smaller research and development companies. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK, and the US and is headquartered in Stockholm, Sweden. For more information on Recipharm and our services, please visit www.recipharm.com About Ahead Therapeutics Ahead Therapeutics is a start-up biotech company that uses proprietary technology to develop treatments for different autoimmune disorders. Ahead Therapeutics has developed an innovative solution based on the use of PS-liposomes containing autoantigens. These liposomes can induce antigen-specific immune tolerance through a biomimetic process, thereby interrupting the autoimmune reaction. Simply by changing the encapsulated autoantigen, Ahead’s technology can address the treatment of different auto-immune diseases: Type 1 Diabetes; Multiple Sclerosis; and Celiac Diseases, among others. For more information, please visit www.aheadtherapeutics.com Recipharm AB Corporate identity number 556498-8425 Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00 www.recipharm.com

GenNext Unveils the World’s First Fully Automated Protein Footprinting System at the California Separation Science Society Meeting

GenNext Technologies, Inc. has announced the release of the AutoFox Protein Footprinting System at the California Separation Science Society combined Mass Spectrometry and Higher Order Structure meetings.

GenNext & SCIEX to Co-Market an Advanced High Order Structure Analysis (HOS) Workflow for Biopharmaceutical Research

GenNext Technologies, Inc. has revealed their agreement to co-market a robust, full-solution workflow for Hydroxyl Radical Protein Footprinting studies with SCIEX.

Blue Spark Technologies Adds Amir Lahav to Key Opinion Leader Advisory Group

Blue Spark Technologies, Inc., a leader in wearable remote patient monitoring solutions, has added Amir Lahav, a clinical leader and established neuroscientist with 20 years of experience to its advisory board.

CD Genomics Unveils A Pioneering Genomics Approach—Long Amplicon Analysis (LAA) Service

CD Genomics Revolutionizes Pathogen Discovery with the Launch of Viral Metagenomic Sequencing Service

Dr. Vince Clinical Research, Clario Form Strategic Partnership to Deliver Innovative Cardiac Assessments in Clinical Trials

Dr. Vince Clinical Research (DVCR), an early phase Clinical Research Organization (CRO), today announced a new collaboration with Clario, a leading healthcare research and technology company that delivers leading endpoint technology solutions for clinical trials.

Barry Simms Named as Elligo Health Research’s Chief Operating Officer

Elligo Health Research®, the largest healthcare-enabling research organization, today announced the addition of Barry Simms as Elligo’s Chief Operating Officer (COO). Simms’ expertise in global strategy and partnerships will help further the company’s growth and mission of providing everyone with easy access to participation in research and to accelerate clinical trials along the way.